Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC
Status:
Completed
Trial end date:
2019-07-22
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, nonrandomized, dose-escalation, Phase 1b study of
carotuximab in combination with standard dose nivolumab in patients with NSCLC that has
progressed on or after platinum-based chemotherapy or PD-1/PD-L1 checkpoint inhibition, as a
single agent or with chemotherapy.